BACKGROUND: The main objective was to identify risk factors for extent progression in distal ulcerative colitis. The secondary objective was to determine clinical characteristics of disease at the time of progression. METHODS: Data were obtained from a prospective database. Distal colitis was defined as disease limited to rectum and sigmoid colon (n = 178), extensive colitis as involvement of at least the descending colon (n = 179), and colitis with progression when there was a change of category from distal to extensive (n = 63). To study clinical characteristics at the time of progression, a nested case-control study was performed. RESULTS: Compared to distal colitis, colitis with progression was associated to significantly higher prevalence of extraintestinal manifestations (42.9% versus 15.5%) steroid-refractory course (28.0% versus 2.2%), requirement of thiopurines (44.3% versus 17.3%), cyclosporine (25.4% versus 1.9%), infliximab (9.5% versus 1.2%), surgery (20.6% versus 0.6%), and incidence of neoplasia (6.3% versus 0%). However, these differences appeared after disease progression. Regression analysis demonstrated that preexisting independent predictive factors for progression were younger age at diagnosis (hazard ratio [HR] 0.979 95% confidence interval [CI] 0.959-0.999) and presence of sclerosing cholangitis (HR 12.83, 95% CI 1.36-121.10). The nested case-control study showed that at the time of progression the flare was more severe in cases than in matched controls, with significant differences in markers of disease severity, therapeutic requirements, hospitalizations, and surgery. CONCLUSIONS: Patients with distal ulcerative colitis diagnosed at a younger age or with associated sclerosing cholangitis are at higher risk for progression. Disease flare associated with progression follows a severe course with high therapeutic requirements.
BACKGROUND: The main objective was to identify risk factors for extent progression in distal ulcerative colitis. The secondary objective was to determine clinical characteristics of disease at the time of progression. METHODS: Data were obtained from a prospective database. Distal colitis was defined as disease limited to rectum and sigmoid colon (n = 178), extensive colitis as involvement of at least the descending colon (n = 179), and colitis with progression when there was a change of category from distal to extensive (n = 63). To study clinical characteristics at the time of progression, a nested case-control study was performed. RESULTS: Compared to distal colitis, colitis with progression was associated to significantly higher prevalence of extraintestinal manifestations (42.9% versus 15.5%) steroid-refractory course (28.0% versus 2.2%), requirement of thiopurines (44.3% versus 17.3%), cyclosporine (25.4% versus 1.9%), infliximab (9.5% versus 1.2%), surgery (20.6% versus 0.6%), and incidence of neoplasia (6.3% versus 0%). However, these differences appeared after disease progression. Regression analysis demonstrated that preexisting independent predictive factors for progression were younger age at diagnosis (hazard ratio [HR] 0.979 95% confidence interval [CI] 0.959-0.999) and presence of sclerosing cholangitis (HR 12.83, 95% CI 1.36-121.10). The nested case-control study showed that at the time of progression the flare was more severe in cases than in matched controls, with significant differences in markers of disease severity, therapeutic requirements, hospitalizations, and surgery. CONCLUSIONS:Patients with distal ulcerative colitis diagnosed at a younger age or with associated sclerosing cholangitis are at higher risk for progression. Disease flare associated with progression follows a severe course with high therapeutic requirements.
Authors: Andreas Stallmach; Luisa Nickel; Thomas Lehmann; Bernd Bokemeyer; Martin Bürger; Dietrich Hüppe; Wolfgang Kruis; Susanna Nikolaus; Jan C Preiss; Andreas Sturm; Niels Teich; Carsten Schmidt Journal: World J Gastroenterol Date: 2014-09-21 Impact factor: 5.742
Authors: D G Ribaldone; I Dileo; R Pellicano; A Resegotti; S Fagoonee; M Vernero; G Saracco; M Astegiano Journal: Ir J Med Sci Date: 2017-07-29 Impact factor: 1.568
Authors: R M Corcoran; P MacDonagh; F O'Connell; M E Morrissey; M R Dunne; R Argue; J O'Sullivan; D Kevans Journal: Dig Dis Sci Date: 2022-03-14 Impact factor: 3.199
Authors: Sandro da Costa Ferreira; Lilian Rose Otoboni Aprile; Rogério Serafim Parra; Marley Ribeiro Feitosa; Gleici de Castro da Silva Perdoná; Omar Féres; José Joaquim Ribeiro da Rocha; Luiz Ernesto de Almeida Troncon Journal: Turk J Gastroenterol Date: 2022-04 Impact factor: 1.555
Authors: Britt Christensen; Stephen B Hanauer; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin Journal: J Crohns Colitis Date: 2020-10-05 Impact factor: 10.020